Ascentage Pharma Updates RSU and Share Option Scheme Mandate Dates

On July 13, 2026, Ascentage Pharma Group International issued a Form 6-K to provide a clarifying update regarding the grant of Restricted Share Units (RSUs) and options. Specifically, the company updated a previous announcement dated June 29, 2026, concerning the further grant of awards under its 2021 RSU Scheme, 2022 RSU Scheme, and the further grant of options under the Post-IPO Share Option Scheme. The update clarifies that the Scheme Mandate Limit, which governs the satisfaction of these 2021 Awards, 2022 Awards, and Options, was established at the annual general meeting held on May 19, 2025, rather than the previously stated date of May 20, 2026. All other terms and information from the original June 29 announcement remain unchanged and valid. This filing serves as a technical correction to the administrative record of the company's equity incentive plans and does not reflect a change in the quantity or terms of the granted awards themselves.